Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Digestive Health Specialists of the Southeast
Dothan, Alabama, United States
Advanced Gastro P.C
Chandler, Arizona, United States
Reliance Research
Scottsdale, Arizona, United States
Moore Clinical Trials, LLC
Little Rock, Arkansas, United States
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States
Om Research LLC
Lancaster, California, United States
United Gastroenterologists
Los Alamitos, California, United States
Paul Wallace MD
Los Angeles, California, United States
Clinnova Research
Orange, California, United States
Digestive System Healthcare
Pasadena, California, United States
Start Date
January 19, 2022
Primary Completion Date
July 4, 2023
Completion Date
October 30, 2028
Last Updated
February 13, 2026
350
ACTUAL participants
Guselkumab Dose 1
DRUG
Guselkumab Dose 2
DRUG
Guselkumab Dose 3
DRUG
Placebo
DRUG
Lead Sponsor
Janssen Research & Development, LLC
NCT07245394
NCT07089420
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions